Recurrence of LV Thrombus in a Patient with Severe Ischaemic Cardiomyopathy Anticoagulated with Apixaban.

Autor: Farooqui A; Department of Cardiology, Kettering General Hospital NS Foundation Trust, Rothwell Road, Kettering, NN16 8UZ, UK.; University Hospitals of Leicester NHS Trust, Leicester, UK., Lwin T; Department of Cardiology, Kettering General Hospital NS Foundation Trust, Rothwell Road, Kettering, NN16 8UZ, UK.; Department of Cardiology, Castle Hill Hospital, UK., Costa D; Department of Cardiology, Kettering General Hospital NS Foundation Trust, Rothwell Road, Kettering, NN16 8UZ, UK., Hetherington S; Department of Cardiology, Kettering General Hospital NS Foundation Trust, Rothwell Road, Kettering, NN16 8UZ, UK.; University of Leicester, Leicester, UK., Mattu R; Department of Cardiology, Kettering General Hospital NS Foundation Trust, Rothwell Road, Kettering, NN16 8UZ, UK.; University College London, London, UK.
Jazyk: angličtina
Zdroj: Case reports in cardiology [Case Rep Cardiol] 2022 Jul 21; Vol. 2022, pp. 8156942. Date of Electronic Publication: 2022 Jul 21 (Print Publication: 2022).
DOI: 10.1155/2022/8156942
Abstrakt: Background: Anticoagulation with warfarin remains the mainstay treatment for left ventricular thrombi. Although successful thrombus resolution has been reported with direct oral anticoagulants' (DOACs') recurrence/progression while resuming Apixaban therapy is yet to be reported. Case Presentation . This case report describes left ventricular thrombus progression/recurrence in a patient anticoagulated with Apixaban undergoing implantable cardioverter defibrillator to cardiac resynchronisation therapy with defibrillator upgrade procedure. He was thereafter changed to warfarin. Contrast echocardiogram at 6 months follow-up did not identify the previously demonstrated mural thrombus.
Conclusion: Prospective randomised control trials should be conducted in patients with left ventricular thrombus to compare anticoagulants, assess the efficacy and safety of DOACs, and evaluate uninterrupted DOAC versus transient withdrawal for cardiac device procedures.
Competing Interests: All authors declare that they have no conflicts of interest.
(Copyright © 2022 Azhar Farooqui et al.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje